Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis.

Quartuccio, Luca; Treppo, Elena; Binutti, Marco; Del Frate, Giulia; De Vita, Salvatore

Quartuccio, Luca; Treppo, Elena; Binutti, Marco; Del Frate, Giulia; De Vita, Salvatore.

Quartuccio L; Department of Medicine (DAME), Rheumatology Clinic ASUFC, University of Udine, Udine, Italy.
Treppo E; Department of Medicine (DAME), Rheumatology Clinic ASUFC, University of Udine, Udine, Italy.
Binutti M; Department of Medicine (DAME), Rheumatology Clinic ASUFC, University of Udine, Udine, Italy.
Del Frate G; Department of Medicine (DAME), Rheumatology Clinic ASUFC, University of Udine, Udine, Italy.
De Vita S; Department of Medicine (DAME), Rheumatology Clinic ASUFC, University of Udine, Udine, Italy.

Rheumatology (Oxford) ; 60(7): 3476-3477, 2021 07 01.

Article in English | MEDLINE | ID: covidwho-1091216

Subject(s)

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; COVID-19; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy; Antibodies, Antineutrophil Cytoplasmic; Humans; Rituximab; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Rheumatology (Oxford) Journal subject: Rheumatology Year: 2021 Document Type: Article Affiliation country: Rheumatology

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google